ELDN Stock Analysis: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$3.88
-0.08 (-1.90%)
▼
5d:
+11.35%
30d:
-0.39%
90d:
+34.08%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ELDN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ELDN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $3.88, which is considered extended relative to its 30-day fair value range of $3.51 to $3.87.
Technical Outlook: Technically, ELDN is in a strong uptrend. The price is approaching resistance at $3.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELDN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.20 (+107.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELDN is in a strong uptrend. The price is approaching resistance at $3.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELDN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.20 (+107.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.51 -
$3.87
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 107.6% below Wall St target ($8.20)
Trading Range Analysis
30-Day Trading Range
$3.51 -
$3.87
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.38
Resistance Level
$3.97
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.46
Wall Street Target
$8.20
(+107.6%)
Share & Embed Analysis
Last updated: June 24, 2026 3:42 PM ET
Data refreshes hourly during market hours. Next update: 4:42 PM
Data refreshes hourly during market hours. Next update: 4:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |
